Cogstate Ltd (ASX: CGS) shares are in focus today after a big climb yesterday.Â
The ASX healthcare stock was one of many ASX shares to enjoy a strong rebound after President Trump set a deadline for Iran to reopen the Strait of Hormuz.
Cogsgate shares jumped an impressive 12% during yesterday’s trading session.
Why did Cogstate shares climb yesterday?
It seems investors were reacting positively to not only international market tailwinds, but also to the company’s 3Q26 Business Update.
Cogstate is a neuroscience technology company specialising in brain health assessments. The principal activity of the company is the sale of technology and services to measure cognition.
In yesterday’s release, the company said it continues to demonstrate strong demand across an expanding range of Central Nervous System (CNS) indications, consistent with trends outlined with the release of the 1H26 financial results.
The company reported total contracted revenue, as at 31-Mar-26, has increased reflecting the sales contracts executed during the quarter:
- Contracted revenue for the June 2026 half year (2H26), including revenue recognised during 3Q26, is $29.1 million, up from $21.7 million under contract at 31-Dec-25.
- This brings full year FY26 revenue under contract (including first half actual of $26.9 million) to $56.0 million (FY25 total revenue was $53.1 million).
- Contracted revenue for next financial year (FY27) is $35.6 million, up from $27.0 million under contract at 31-Dec-25.
What did Bell Potter have to say?
Following this release, the team at Bell Potter provided updated guidance on Cogsgate shares.
The broker said the strong sales momentum is continuing for the healthcare stock, with the recent results representing the best quarter of new sales in at least 3 years.
Bell Potter said it was clearly a positive update, which increases confidence that the diversification and strong momentum seen in 1H26 was not just a ‘one-off’ and further growth in the revenue backlog looks likely.
Following the strong sales update, he broker has lifted its FY27 revenue forecast by 3% and its FY28 forecast by 5%.
Our updated FY26 forecast implies $3.2m of in-period additions in Q4 which seems quite achievable.
Buy recommendation in tact
The broker also reiterated its buy recommendation for Cogsgate shares, along with increasing its price target to $3.20 (previously $2.90).
The broker said the company is trading at a discount to global peers (13x on avg) despite having a far more attractive topline growth outlook.
From yesterday’s closing price of $2.40, the updated price target from Bell Potter indicates a potential upside of 33%.
The post Are Cogsgate shares a buy, hold or sell after rocketing 12% higher yesterday? appeared first on The Motley Fool Australia.
Should you invest $1,000 in CogState Limited right now?
Before you buy CogState Limited shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CogState Limited wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cogstate. The Motley Fool Australia has positions in and has recommended Cogstate. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.